background previous metaanalyses of published and unpublished trials indicate that antidepressants provide modest benefits compared to placebo in the treatment of depression some have argued that these benefits are not clinically significanthowever these metaanalyses were based only on trials submitted for the initial fda approval of the medication and were limited to those aimed at treating depressionhere for the first time we assess the efficacy of a selective serotonin reuptake inhibitor ssri in the treatment of both anxiety and depression using a complete data set of all published and unpublished trials sponsored by the manufacturermethods and findings glaxosmithkline has been required to post the results for all sponsored clinical trials online providing an opportunity to assess the efficacy of an ssri paroxetine with a complete data set of all trials conductedwe examined the data from all placebocontrolled doubleblind trials of paroxetine that included change scores on the hamilton rating scale for anxiety hrsa andor the hamilton rating scale for depression hrsdfor the treatment of anxiety k  12 the efficacy difference between paroxetine and placebo was modest d  027 and independent of baseline severity of anxietyoverall change in placebotreated individuals replicated 79 of the magnitude of paroxetine responseefficacy was superior for the treatment of panic disorder d  036 than for generalized anxiety disorder d  020published trials showed significantly larger drugplacebo differences than unpublished trials ds  032 and 017 respectivelyin depression trials k  27 the benefit of paroxetine over placebo was consistent with previous metaanalyses of antidepressant efficacy d  032conclusions the available empirical evidence indicates that paroxetine provides only a modest advantage over placebo in treatment of anxiety and depressiontreatment implications are discussed